OPR - Delayed Quote • USD EPIX Jul 2024 7.500 call (EPIX240719C00007500) Follow 0.9200 0.0000 (0.00%) As of April 24 at 12:59 PM EDT. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for EPIX240719C00007500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: EPIX ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference ESSA Pharma (NASDAQ:EPIX) Is In A Strong Position To Grow Its Business ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS 12 $10 Stocks That Will Triple EPIX: Risk Profile of Patients in Phase 1/2 Trial of Masofaniten Reveals Majority at High Risk for Early Enzalutamide Failure… ESSA Pharma Inc (EPIX) Reports Q1 Fiscal 2024 Financial Results ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023 ESSA Pharma Inc Executive Peter Virsik Sells 72,782 Shares ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference EPIX: Updated Data for Phase 1 Trial of Masofaniten Shows 63% of Patients Achieved PSA <0.2 ng/mL… ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium ESSA Pharma Inc.'s (NASDAQ:EPIX) hedge funds investors lost 12% last week but have benefitted from longer-term gains
